News

Press Release 09.04.2024 FORE Biotherapeutics announces new nonclinical data highlighting the differentiation of plixorafenib in combination with MEK inhibition at #AACR24 Read more

Press Release 29.02.2024 FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer Read more

Press Release 01.02.2024 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more

Press Release 07.12.2023 FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Private Company Conference Read more

Press Release 17.11.2023 FORE Biotherapeutics Announces Oral Presentation at SNO 2023 Reporting Updated Phase 1/2a Results for Plixorafenib in BRAF V600 Advanced Solid Tumors, Including Novel Data for Patients with BRAF V600 Primary CNS Tumors Read more

Press Release 10.11.2023 FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting Read more

Press Release 12.10.2023 FORE Biotherapeutics to Present Plixorafenib Nonclinical Data Highlighting Potential Differentiation at the 2023 AACR-NCI-EORTC International Conference Read more

Press Release 23.08.2023 FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition Read more

Press Release 26.05.2023 FORE Biotherapeutics to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib (FORE8394) in Patients With BRAF-Altered Advanced Solid and Central Nervous System Tumors at ASCO 2023 Read more